Article Dans Une Revue Cells Année : 2024

Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Pierre Stéphan
  • Fonction : Auteur
  • PersonId : 1505442
Yann Guillermin
  • Fonction : Auteur
  • PersonId : 1505443
Anne-Sophie Michallet

Résumé

Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular efficacy of Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), resistance can develop in CLL patients, and alternative therapeutic strategies are therefore required. Cancer immunotherapy has revolutionized cancer care and may be an attractive approach in this context. We speculated that characterizing the immune responses of CLL patients may highlight putative immunotherapeutic targets. Here, we used high-dimensional spectral flow cytometry to compare the distribution and phenotype of non-B-cell immune populations in the circulating blood of CLL patients treated with Ibrutinib displaying a complete response or secondary progression. Although no drastic changes were observed in the composition of their immune subsets, the Ibrutinib-resistant group showed increased cycling of CD8+ T cells, leading to their overabundance at the expense of dendritic cells. In addition, the expression of 11 different surface checkpoints was similar regardless of response status. Together, this suggests that CLL relapse upon Ibrutinib treatment may not lead to major alterations in the peripheral immune response.

Fichier principal
Vignette du fichier
cells-13-01458.pdf (6) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04941279 , version 1 (11-02-2025)

Licence

Identifiants

Citer

Pierre Stéphan, Khaled Bouherrou, Yann Guillermin, Anne-Sophie Michallet, Yenkel Grinberg-Bleyer. Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cells, 2024, Onco-Hematology and Immunotherapy, 13, ⟨10.3390/cells13171458⟩. ⟨hal-04941279⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More